Vnitr Lek 2023, 69(2):133-137 | DOI: 10.36290/vnl.2023.021

News in immunology

Jiřina Bartůňková, Markéta Bloomfield, Magdalena Havlišová, Adam Klocperk, Helena Kubešová, Michal Podrazil, Zuzana Střížová, Anna Šedivá
Ústav imunologie 2. LF UK a FN v Motole, Praha

The field of immunology has undergone a very significant development in recent decades, which has been reflected especially in the beginning of this millennium in significant advances in the understanding of the immune system and in the application of this knowledge in practice. The progress and acceleration of research and advances in the field of immunology was further prompt by the unexpected onset of the COVID-19 pandemic in 2020. The intense scientific work has not only led to the development of our understanding of the immune response to viruses, but also to the rapid conversion of this knowledge into practical pandemic management on a global scale, as exemplified by the development of vaccines against SARS-Cov-2 virus. The pandemic era has further contributed to the acceleration of the application of not only biological discoveries but also technological approaches into practical applications, such as use of advanced mathematics, computer science and, more recently, artificial intelligence which are all are adding to the advances that are significantly moving the field of immunology forward. In this communication, we present specific advances in particular areas of immunopathology, which are mainly allergy, immunodeficiency, immunity and infection, vaccination, autoimmune diseases and cancer immunology.

Keywords: allergy, immunodeficiency, immunity, infection, vaccination, autoimmune disease, cancer.

Accepted: March 23, 2023; Published: March 30, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bartůňková J, Bloomfield M, Havlišová M, Klocperk A, Kubešová H, Podrazil M, et al.. News in immunology. Vnitr Lek. 2023;69(2):133-137. doi: 10.36290/vnl.2023.021.
Download citation

References

  1. Calhoun WJ. The new era of add‑on asthma treatments: where do we stand? Allergy Asthma Clin Immunol. 2022;18(1):42. Go to original source...
  2. Atanasio A. Biologics as novel therapeutics for the treatment of allergy: Challenges and opportunities. Front Allergy. 2022;3:1019255. Go to original source... Go to PubMed...
  3. Global Initiative for Asthma Global strategy for asthma management and prevention. Updated 2022. www.ginasthma.org.
  4. Tangye SG, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J. Clin. Immunol. (2022) doi:10.1007/s10875-022-01289-3. Go to original source... Go to PubMed...
  5. Blom M, et al. Second Tier Testing to Reduce the Number of Non‑actionable Secondary Findings and False‑Positive Referrals in Newborn Screening for Severe Combined Immunodeficiency. J. Clin. Immunol. 41, 1762-1773 (2021). Go to original source...
  6. McInnes IB, Gravallese EM.Immune‑mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol. 2021;21(10):680-686. Go to original source... Go to PubMed...
  7. Powers AC. Type 1 diabetes mellitus: much progress, many opportunities. J Clin Invest. 2021;131(8):e142242. Go to original source...
  8. Misztal MC, Liao F, Couse M, et al. Genome‑Wide Sequencing Identified Rare Genetic Variants for Childhood‑Onset Monogenic Lupus. J Rheumatol. 2022 Nov 15:jrheum.220513. Go to original source...
  9. Bastard, et al. "Autoantibodies against type I IFNs in patients with life‑threatening COVID-19." Science. Sept 2020. doi: 10.1126/science.abd4585. Go to original source... Go to PubMed...
  10. Zhang T, et al. Inborn errors of type I IFN immunity in patients with life‑threatening COVID-19. Science. Sept 2020. doi: 10.1126/science.abd4570. Go to original source... Go to PubMed...
  11. Netea M, et al. Defining trained immunity and its role in health and disease". Nature Reviews. Immunology. 2020(6):375-388. doi:10.1038/s41577-020-0285-6. Go to original source... Go to PubMed...
  12. Piret J, Boivin G. Viral Interference between Respiratory Viruses. Emerg Infect, DiS. Feb 2022;28(2):273-281. doi: 10.3201/eid2802.211727. Go to original source... Go to PubMed...
  13. Maruggi G, Zhang C, Li J, Ulmer J B, Yu D. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol Ther. 2019;27(4):757-772. doi: 10.1016/j.ymthe.2019. 01. 020. Go to original source... Go to PubMed...
  14. Rosa SS, Prazeres DMF, Azevedo AM, Marques MPC. mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine. 2021;39(16):2190-2200. doi: 10.1016/j.vaccine.2021. 03. 038. Go to original source... Go to PubMed...
  15. Steinle H, Behring A, Schlensak C, Wendel H P, Avci‑Adali M. Concise review: application of in vitro transcribed messenger RNA for cellular engineering and reprogramming: progress and challenges. Stem Cells. 2017;35(1):68-79. doi: 10.1002/stem.2402. Go to original source... Go to PubMed...
  16. Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol. 2022;19(1):37-50. doi:10.1038/s41571-021-00552-7. Go to original source... Go to PubMed...
  17. Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody‑Drug Conjugates: A Comprehensive Review. Mol Cancer Res. 2020;18(1):3-19. doi:10.1158/1541-7786.MCR-19-0582 Go to original source... Go to PubMed...
  18. Michielin O, Lalani AK, Robert C, Sharma P, Peters S. Defining unique clinical hallmarks for immune checkpoint inhibitor‑based therapies [published correction appears in J Immunother Cancer. 2022;10(12):]. J Immunother Cancer. 2022;10(1):e003024. doi:10.1136/jitc-2021-003024. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.